Cassava Dives Again After Investors Spooked By Alzheimer’s Drug Fraud Claims
Lab Test Company Did Not Conduct Data Analysis
Executive Summary
Cassava’s claims that its drug reversed cognitive decline in Alzheimer’s patients are seen as "too good to be true" by skeptics. A statement by former lab services partner Quanterix has further undermined investor confidence.
You may also be interested in...
Cassava’s Simufilam Continues To Alienate Investors Despite Some Phase II Alzheimer’s Promise
The US firm is touting top-line data from an open-label Alzheimer’s disease trial as a net positive, but the lack of p-values and a declining trend in efficacy left some investors and analysts lukewarm.
US FDA Quashes Citizen Petition Against Bluebird’s Zynteglo That Cited Patent, Safety Concerns
San Rocco, whose potential rival gene therapy for thalassemia is in preclinical development, had wanted FDA to delay approval of bluebird’s BLA until resolution of a patent case and a ‘careful investigation’ of Zynteglo’s risks.
Vertex’s Sickle Cell Treatment Gets December Decision Date, On Track To Be First CRISPR Therapy
Vertex now looks likely to gain US approval for the first ever CRISPR gene edited therapy by the end of the year, but could face immediate competition from Bluebird Bio.